+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Schizophrenia Drugs Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis

  • PDF Icon

    Report

  • 130 Pages
  • March 2022
  • Region: Global
  • Renub Research
  • ID: 5562677
The Global Schizophrenia Drugs Market is expected to reach U$ 10.15 Billion in 2027. Schizophrenia is a persistent mental illness that harms a person's lifestyle. Furthermore, schizophrenic patients have a distorted perception of reality. The condition causes a variety of behavioral alterations, such as grouping hallucinations, delusions, and so forth. As a result, medicine in schizophrenia pharmaceuticals is used to treat schizophrenia, which controls patients' behavior. These drugs regulate dopamine levels in the brain, thus the schizophrenia patient's general behavior. Furthermore, the pharmacological treatment for schizophrenia is a lifelong process.



Worldwide Schizophrenia Drugs Market will be worth US$ 8.02 Billion in 2021


The schizophrenia market has remained replete with significant unmet demands over time. The presence of favorable reimbursement policies and unmet requirements in the market is expected to provide lucrative prospects for market participants. Furthermore, the market can be driven by a growth in the number of patients seeking treatment and rising demand for improved healthcare infrastructure. In addition, advancing innovation in drug delivery methods is expected to drive market growth throughout the forecast period. Market evolution is expected to be aided by increased government expenditure on healthcare infrastructure. Furthermore, the industry is being driven by the expanding elderly population.

COVID-19 Impact Worldwide Schizophrenia Drugs Industry:


The COVID-19 pandemic had the potential to impact mental health significantly. Those with schizophrenia were the most brutal hit. If exposed, patients were at a greater risk of contracting the COVID-19 virus. Because of their difficulty in following safety precautions, schizophrenic patients were shown to be at a higher risk of infection. However, during the pandemic, the market for schizophrenia medications grew because people with schizophrenia had difficulty adhering to proper hygiene practices, owing to impaired judgment and self-care. According to our estimate, global schizophrenia drugs industry will expand with a CAGR of 4% during 2021-2027.

The Second Generation Segment Is Projected to Render the Highest Revenue During the Forecast Period:


One of the most important criteria for a schizophrenia therapy product is its higher efficacy and safety. There was a higher reliance on first-generation medications for schizophrenia in prior decades, but their use was also associated with several significant side effects. The patient's condition or prognosis was frequently exacerbated due to these side effects. As a result, more concentration was paid to creating atypical antipsychotics, also known as second generation medicines, which have higher efficacy and a lower number of side effects.

Injectable-Based Treatment of Schizophrenia Exhibits a Significant Growth During the Forecast Period:


Several new essential products have been launched due to the increased number of people suffering from schizophrenia and increased knowledge about mental conditions. In addition, some major participants in the schizophrenia therapy industry have robust R&D pipelines. As a result, two forms of schizophrenia therapies have emerged: oral and injectable. Because of the benefits connected with injectable treatments, they are becoming more popular.

Injectable-based schizophrenia medicines, particularly long-acting injectables, are among the most advanced kinds of treatment (LAIs). Long-acting injectables can often help eliminate the side effects of oral schizophrenia treatment. As a result of these treatment modes' improving efficacy and safety, there is a greater adoption and transfer to injectable schizophrenia medications.

Increasing Admission to The Internet Facilities Globally Boosts the Market for Online Pharmacies:


Customers are an essential aspect of the schizophrenia therapeutics market and are expected to be a critical determining factor in the distribution channel's dominance. The retail pharmacies segment is expected to be the most prevalent in the distribution channel segment, owing to the fulfilment of prescriptions following the first diagnosis.

Furthermore, online pharmacies are expected to develop due to increased global access to internet services and the resulting comfort and ease of ordering or filling prescriptions from the comfort of one's own home or other location. Every retail sector's core function is an online pharmacy. Many retail outlets now have vast amounts of data about their consumers, stores, and market competitors, which they may use to grow their customer base effectively.

Asia Pacific Is Expected to Witness the Highest Growth in The Market:


According to our estimates, the worldwide schizophrenia medications market would be dominated by North America over the forecast period. The region's market development is likely fuelled by the growing acceptance of modern schizophrenia medications. Furthermore, rising awareness, desire for effective treatments, and an increasing number of schizophrenic patients are likely to drive the growth of the schizophrenia drugs market in North America throughout the forecast period.

Contrarily, the Asia Pacific is predicted to develop at the fastest rate in the market. A key driver for the industry in the region is increased awareness and attention on mental health. Healthcare professionals and enterprises in India, China, Japan, and the rest of Asia Pacific are interested in the effective administration of schizophrenia medicines and the region's new product introductions.

Key Players:


Several competitors in the schizophrenia treatment market are focusing on forming commercialization and research alliances to capitalize on opportunities. Compared to mergers and acquisitions, the synergy created through collaborations and partnerships has a favourable and immediate influence on growth. Furthermore, leading players in the schizophrenia medication industry are focused on emerging markets for possible growth prospects and capturing new revenue streams. Alkermes plc, AstraZeneca, Eli Lilly and Company, Johnson & Johnson, Pfizer, Inc, Sumitomo Dainippon Pharma Co., Ltd., Vanda Pharmaceuticals Inc., GlaxoSmithKline plc, Teva Pharmaceuticals, and AbbVie Inc. are among the key market players included in the analysis.

The publisher's latest report Schizophrenia Drug Market, By Class (First Generation, Second Generation, Third Generation), Treatment Market Analysis (Oral, Injection), End-User (Hospital, Retails, Online), Region (North America, Europe, Asia Pacific, South America, Middle East & Africa), Companies (Alkermes plc, AstraZeneca, Eli Lilly and Company, Johnson & Johnson, Pfizer, Inc, Sumitomo Dainippon Pharma Co., Ltd., Vanda Pharmaceuticals Inc., GlaxoSmithKline plc, Teva Pharmaceuticals, and AbbVie Inc.) provides a detailed analysis of Schizophrenia Drug Industry.

Class - Market has been covered from 3 viewpoints:


1. First Generation
2. Second Generation
3. Third Generation

Treatment - Market has been covered from 2 viewpoints:


1. Oral
2. Injection

End-User - Market has been covered from 3 viewpoints:


1. Hospital
2. Retails
3. Online

Region - Market has been covered from 5 viewpoints:


1. North America
2. Europe
3. Asia Pacific
4. South America
5. Middle East & Africa

Company Insights:


  • Overview
  • Business Strategy
  • Financial Insight

Company Analysis:


1. Alkermes plc
2. AstraZeneca
3. Eli Lilly and Company
4. Johnson & Johnson
5. Pfizer, Inc
6. Sumitomo Dainippon Pharma Co., Ltd.
7. Vanda Pharmaceuticals Inc.
8. GlaxoSmithKline plc
9. Teva Pharmaceuticals
10. AbbVie Inc.

Table of Contents

1. Introduction2. Research & Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Schizophrenia Drug Market
6. Market Share - Global Schizophrenia Drugs Analysis
6.1 By Class
6.2 By Treatment
6.3 By End-users
6.4 By Regions
7. Class - Global Schizophrenia Drug Market
7.1 First Generation
7.2 Second Generation
7.3 Third Generation
8. Treatment - Global Schizophrenia Drug Market
8.1 Oral
8.2 Injection
9. End-User - Global Schizophrenia Drug Market
9.1 Hospital
9.2 Retails
9.3 Online
10. Region - Global Schizophrenia Drug Market
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 South America
10.5 Middle East & Africa
11. Porters Five Forces
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12. Company Analysis
12.1 Alkermes plc
12.1.1 Overview
12.1.2 Business Strategy
12.1.3 Financial Insight
12.2 AstraZeneca
12.2.1 Overview
12.2.2 Business Strategy
12.2.3 Financial Insight
12.3 Eli Lilly and Company
12.3.1 Overview
12.3.2 Business Strategy
12.3.3 Financial Insight
12.4 Johnson & Johnson
12.4.1 Overview
12.4.2 Business Strategy
12.4.3 Financial Insight
12.5 Pfizer, Inc
12.5.1 Overview
12.5.2 Business Strategy
12.5.3 Financial Insight
12.6 Sumitomo Dainippon Pharma Co., Ltd.
12.6.1 Overview
12.6.2 Business Strategy
12.6.3 Financial Insight
12.7 Vanda Pharmaceuticals Inc.
12.7.1 Overview
12.7.2 Business Strategy
12.7.3 Financial Insight
12.8 GlaxoSmithKline plc
12.8.1 Overview
12.8.2 Business Strategy
12.8.3 Financial Insight
12.9 Teva Pharmaceuticals
12.9.1 Overview
12.9.2 Business Strategy
12.9.3 Financial Insight
12.10 AbbVie Inc.
12.10.1 Overview
12.10.2 Business Strategy
12.10.3 Financial Insight
List Of Figures:
Figure 01: Global - Schizophrenia Drug Market (Billion US$), 2016 - 2021
Figure 02: Global - Forecast for Schizophrenia Drug Market (Billion US$), 2022 - 2027
Figure 03: Class - First Generation Market (Million US$), 2016 - 2021
Figure 04: Class - Forecast for First Generation Market (Million US$), 2022 - 2027
Figure 05: Class - Second Generation Market (Million US$), 2016 - 2021
Figure 06: Class - Forecast for Second Generation Market (Million US$), 2022 - 2027
Figure 07: Class - Third Generation Market (Million US$), 2016 - 2021
Figure 08: Class - Forecast for Third Generation Market (Million US$), 2022 - 2027
Figure 09: Treatment - Oral Market (Million US$), 2016 - 2021
Figure 10: Treatment - Forecast for Oral Market (Million US$), 2022 - 2027
Figure 11: Treatment - Injection Market (Million US$), 2016 - 2021
Figure 12: Treatment - Forecast for Injection Market (Million US$), 2022 - 2027
Figure 13: End User - Hospital Market (Million US$), 2016 - 2021
Figure 14: End User - Forecast for Hospital Market (Million US$), 2022 - 2027
Figure 15: End User - Retails Market (Million US$), 2016 - 2021
Figure 16: End User - Forecast for Retails Market (Million US$), 2022 - 2027
Figure 17: End User - Online Market (Million US$), 2016 - 2021
Figure 18: End User - Forecast for Online Market (Million US$), 2022 - 2027
Figure 19: North America - Schizophrenia Drug Market (Million US$), 2016 - 2021
Figure 20: North America - Forecast for Schizophrenia Drug Market (Million US$), 2022 - 2027
Figure 21: Europe - Schizophrenia Drug Market (Million US$), 2016 - 2021
Figure 22: Europe - Forecast for Schizophrenia Drug Market (Million US$), 2022 - 2027
Figure 23: Asia Pacific - Schizophrenia Drug Market (Million US$), 2016 - 2021
Figure 24: Asia Pacific - Forecast for Schizophrenia Drug Market (Million US$), 2022 - 2027
Figure 25: South America - Schizophrenia Drug Market (Million US$), 2016 - 2021
Figure 26: South America - Forecast for Schizophrenia Drug Market (Million US$), 2022 - 2027
Figure 27: Middle East & Africa - Schizophrenia Drug Market (Million US$), 2016 - 2021
Figure 28: Middle East & Africa - Forecast for Schizophrenia Drug Market (Million US$), 2022 - 2027
Figure 29: Alkermes plc - Global Revenue (Million US$), 2016 - 2021
Figure 30: Alkermes plc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 31: AstraZeneca - Global Revenue (Million US$), 2016 - 2021
Figure 32: AstraZeneca - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 33: Eli Lilly and Company - Global Revenue (Million US$), 2016 - 2021
Figure 34: Eli Lilly and Company - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 35: Johnson & Johnson - Global Revenue (Million US$), 2016 - 2021
Figure 36: Johnson & Johnson - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 37: Pfizer, Inc - Global Revenue (Million US$), 2016 - 2021
Figure 38: Pfizer, Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 39: Sumitomo Dainippon Pharma Co., Ltd. - Global Revenue (Million US$), 2016 - 2021
Figure 40: Sumitomo Dainippon Pharma Co., Ltd. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 41: Vanda Pharmaceuticals Inc. - Global Revenue (Million US$), 2016 - 2021
Figure 42: Vanda Pharmaceuticals Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 43: GlaxoSmithKline plc - Global Revenue (Million US$), 2016 - 2021
Figure 44: GlaxoSmithKline plc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 45: Teva Pharmaceuticals - Global Revenue (Million US$), 2016 - 2021
Figure 46: Teva Pharmaceuticals - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 47: AbbVie Inc. - Global Revenue (Million US$), 2016 - 2021
Figure 48: AbbVie Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
List Of Tables:
Table 01: Global - Schizophrenia Drug Market Share by Class (Percent), 2016 - 2021
Table 02: Global - Forecast for Schizophrenia Drug Market Share by Class (Percent), 2022 - 2027
Table 03: Global - Schizophrenia Drug Market Share by Treatment (Percent), 2016 - 2021
Table 04: Global - Forecast for Schizophrenia Drug Market Share by Treatment (Percent), 2022 - 2027
Table 05: Global - Schizophrenia Drug Market Share by End User (Percent), 2016 - 2021
Table 06: Global - Forecast for Schizophrenia Drug Market Share by End User (Percent), 2022 - 2027
Table 07: Global - Schizophrenia Drug Market Share by Region (Percent), 2016 - 2021
Table 08: Global - Forecast for Schizophrenia Drug Market Share by Region (Percent), 2022 - 2027

Companies Mentioned

  • Alkermes plc
  • AstraZeneca
  • Eli Lilly and Company
  • Johnson & Johnson
  • Pfizer, Inc
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Vanda Pharmaceuticals Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals
  • AbbVie Inc.

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Table Information